TargetCaRe is a Marie Sklodowska-Curie Innovative Training Network (MSCA-ITN) on targeting cartilage regeneration in joints and intervertebral disc diseases in the Horzion2020 programme of the European Union. In total, 15 Early Stage Researchers (ESRs) will be appointed by the TargetCaRe consortium for 36 months each.

TargetCaRe project summary
Mobility is very important for human well-being, but is seriously impaired by chronic low back pain and osteoarthritis in many people worldwide. This is due to degeneration of the cartilaginous tissue of the intervertebral disc and joint. To develop a treatment for these diseases, in the TargetCaRe consortium novel highly advanced drug delivery carriers with dedicated targeting tools, state of the art imaging techniques and expertise in stem cell and joint biology are combined.

The aim is to achieve regeneration of damaged and degenerated tissues by employing targeting strategies tailored to both the pathology and the tissues involved. Regeneration of diseased tissues will be achieved by loading biologically active agents in state-of-the-art nanocarriers. The biologically active agents will stimulate the body’s intrinsic capacity to regenerate by attracting local stem cells or inhibit degeneration.

Further details:
http://www.nature.com